Ekso Bionics Holdings (NASDAQ: EKSO) and Unilife Corp (NASDAQ:UNIS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Earnings & Valuation

This table compares Ekso Bionics Holdings and Unilife Corp’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Ekso Bionics Holdings $7.49 million 4.34 -$27.14 million ($1.55) -0.81
Unilife Corp N/A N/A N/A N/A N/A

Unilife Corp has higher revenue, but lower earnings than Ekso Bionics Holdings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Ekso Bionics Holdings and Unilife Corp, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ekso Bionics Holdings 0 0 2 0 3.00
Unilife Corp 0 0 0 0 N/A

Ekso Bionics Holdings currently has a consensus target price of $6.00, indicating a potential upside of 376.19%. Given Ekso Bionics Holdings’ higher probable upside, equities research analysts plainly believe Ekso Bionics Holdings is more favorable than Unilife Corp.

Volatility & Risk

Ekso Bionics Holdings has a beta of -0.93, suggesting that its share price is 193% less volatile than the S&P 500. Comparatively, Unilife Corp has a beta of -0.92, suggesting that its share price is 192% less volatile than the S&P 500.


This table compares Ekso Bionics Holdings and Unilife Corp’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ekso Bionics Holdings -372.20% -798.93% -146.30%
Unilife Corp -654.23% N/A -78.00%

Insider and Institutional Ownership

6.0% of Ekso Bionics Holdings shares are held by institutional investors. Comparatively, 14.9% of Unilife Corp shares are held by institutional investors. 7.1% of Ekso Bionics Holdings shares are held by company insiders. Comparatively, 1.9% of Unilife Corp shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.


Ekso Bionics Holdings beats Unilife Corp on 5 of the 9 factors compared between the two stocks.

About Ekso Bionics Holdings

Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness. The company’s Ekso device is primarily used in a clinic or rehabilitation setting. It also performs research and development work on human exoskeletons and related technologies. The company has a license agreement with Lockheed Martin Corporation to develop products for military applications, as well as with OttoBock Healthcare Products Gmbh. The company was founded in 2005 and is headquartered in Richmond, California. Ekso Bionics Holdings, Inc. operates as a subsidiary of Magee Rehabilitation Hospital.

About Unilife Corp

Unilife Corp is engaged in the designing, development and manufacturing of injectable drug delivery systems. The Company has a portfolio of product platforms, including pre-filled syringes, disposable and reusable auto-injectors, drug reconstitution delivery systems, ocular delivery systems, and other systems for the targeted delivery of injectable therapies. The majority of its products are designed for sale directly to pharmaceutical and biotechnology companies supplying them as drug-device combination products, pre-filled and ready for administration by end-users, such as health-care providers or patients. Its other products, such as reusable auto-injectors and certain systems for targeted drug delivery are designed either to be sold to pharmaceutical or biotechnology companies for use as combination products or to be sold directly to a health care provider or end user without having the device pre-filled by a pharmaceutical company.

Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.